An increase in indoleamine 2, 3-dioxygenase-positive cells in the tumor microenvironment predicts favorable prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. Issue 8 (2nd August 2016) - Nam, Soo Jeong